treatment

Treatment with the HDAC inhibitor trichostatin A delayed disease onset and increased survival time in SOD1 research mice

Posted on Thursday, July 28, 2011 - 13:47, By: Amy Madsen
An experimental compound called trichostatin A (TSA) has been shown to improve nerve-cell survival, increase strength and muscle weight, and result in longer life span in mice with a disease resembling ALS (amyotrophic lateral sclerosis, or Lou Gehrig's disease).

Biotechnology company Cytokinetics has opened enrollment for a phase 2 clinical trial to study its experimental treatment CK-2017357 in ALS

Posted on Friday, July 1, 2011 - 14:34, By: Amy Madsen
San Francisco biotechnology company Cytokinetics announced June 21, 2011, that it has opened enrollment for a new clinical trial of CK-2017357 at three different dosage levels in people with ALS (amyotrophic lateral sclerosis, or Lou Gehrig's disease).

Advertisements

myMuscleTeam